Crown Bioscience LogoCrown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego (CA, USA).

The new services introduce a range of platforms for the evaluation of immuno-oncology programmes, while also adding new technologies for traditional oncology agents. Responding to the global focus on immuno-oncology, CrownBio has added a broad portfolio of highly characterized syngeneic in vivo services and, at the same time, expanded its flow cytometry laboratories to support both syngeneic and humanized PDX studies.

Mike Prosser, CrownBio’s general manager of European and North American operations, commenting on the recently announced site expansion and new offering, said: “Following the recent investment in our US site, we now have the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials) with Humanized NSG xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.”

CrownBio has also developed new PDX derived cell lines to enrich the company’s PrimePanel collection with primary cells from Caucasian, pretreated and metastatic tumour samples to help evaluate traditional oncology agents. Additionally, CrownBio has developed expanded 3D-tumour growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumour microenvironment.

“These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumor microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,” said Jean-Pierre Wery, PhD, CEO of CrownBio.